Pre-made Ensituximab benchmark antibody ( Whole mAb, anti-MUC5AC therapeutic antibody, Anti-MUC5/TBM/leBin Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-187

Pre-Made Ensituximab biosimilar, Whole mAb, Anti-MUC5AC Antibody: Anti-MUC5/TBM/leBin therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ensituximab (NPC-1C) is a chimeric monoclonal antibody under development for as a candidate for treatment of cancers. The target of the antibody is uncertain and is described as "human colorectal and pancreatic carcinoma-associated antigens", a set of tumor antigens isolated from human cancers. The target might be Mucin 5AC.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-187-1mg 1mg 3090 Inquiry Inquiry

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Ensituximab biosimilar, Whole mAb, Anti-MUC5AC Antibody: Anti-MUC5/TBM/leBin therapeutic antibody
INN Name Ensituximab
TargetMUC5AC
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesNeogenix Oncology;Duke University Medical Center;H. Lee Moffitt Cancer Center and Research Institute;Johns Hopkins Medical Institutions;Montefiore Medical Center;National Cancer Institute (USA);Precision Biologics;University of North Carolina;University of Texas Southwestern Medical Center;Yale University School of Medicine
Conditions Approvedna
Conditions ActiveColorectal cancer;Pancreatic cancer
Conditions Discontinuedna
Development Techna